* In April, an electronic investigational new drug (eIND) application for IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidate for the treatment of HIV, was filed to support a phase I study in healthy volunteers.
The creation of a thousand forests is in one acorn.
Market Data 
Markets 
AI
